T. Rowe Price Associates
SRNE

T. Rowe Price Associates’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

T. Rowe Price Associates’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-209,418
Closed -$186K – 2993
2022
Q4 		$186K Buy
209,418
+16,181
+8% +$21.5K ﹤0.01% 2554
2022
Q3 		$304K Buy
193,237
+51,676
+37% +$117K ﹤0.01% 2378
2022
Q2 		$285K Buy
141,561
+10,846
+8% +$18.8K ﹤0.01% 2463
2022
Q1 		$305K Buy
130,715
+18,809
+17% +$58.7K ﹤0.01% 2543
2021
Q4 		$520K Buy
111,906
+9,933
+10% +$61.7K ﹤0.01% 2373
2021
Q3 		$778K Sell
101,973
-22,500
-18% -$191K ﹤0.01% 2170
2021
Q2 		$1.21M Buy
124,473
+13,989
+13% +$111K ﹤0.01% 1992
2021
Q1 		$914K Sell
110,484
-7,891
-7% -$83.3K ﹤0.01% 2100
2020
Q4 		$808K Buy
118,375
+4,222
+4% +$33.9K ﹤0.01% 2039
2020
Q3 		$1.27M Buy
114,153
+41,607
+57% +$381K ﹤0.01% 1705
2020
Q2 		$456K Sell
72,546
-3,643
-5% -$13.9K ﹤0.01% 2085
2020
Q1 		$140K Buy
76,189
+32,000
+72% +$92.2K ﹤0.01% 2370
2019
Q4 		$149K Buy
44,189
+4,864
+12% +$11.6K ﹤0.01% 2432
2019
Q3 		$84K Buy
39,325
+953
+2% +$2.22K ﹤0.01% 2466
2019
Q2 		$102K Buy
38,372
+25,200
+191% +$90.7K ﹤0.01% 2476
2019
Q1 		$63K Buy
13,172
+400
+3% +$1.05K ﹤0.01% 2492
2018
Q4 		$31K Sell
12,772
-60,454
-83% -$197K ﹤0.01% 2540
2018
Q3 		$322K Buy
73,226
+24,653
+51% +$137K ﹤0.01% 2334
2018
Q2 		$350K Buy
48,573
+3,877
+9% +$26.4K ﹤0.01% 2298
2018
Q1 		$230K Sell
44,696
-32,604
-42% -$232K ﹤0.01% 2375
2017
Q4 		$294K Buy
+77,300
New +$201K ﹤0.01% 2290
2015
Q4 		– Sell
-30,462
Closed -$256K – 2549
2015
Q3 		$256K Buy
+30,462
New +$485K ﹤0.01% 2198

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

T. Rowe Price Associates's SRNE Position: Q1 2023 in Review

T. Rowe Price Associates sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 209,418 shares — an estimated $186K sold.

T. Rowe Price Associates first reported a position in SRNE in Q3 2015 and held it in 22 quarters. The position peaked at $1.27M in Q3 2020. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • T. Rowe Price Associates reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • T. Rowe Price Associates sold 209,418 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $186K.
  • T. Rowe Price Associates first reported a position in Sorrento Therapeutics, Inc. in Q3 2015 and held it in 22 quarters.
  • T. Rowe Price Associates's Sorrento Therapeutics, Inc. position peaked at $1.27M in Q3 2020.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on T. Rowe Price Associates's 13F filing for Q1 2023, filed 15 May 2023.